Intellectual Property

Hemostemix’s proprietary technology is protected by an extensive portfolio of issued and pending patents throughout the United States, Canada, Europe, Japan and China related to the collection, processing and manufacture of therapies from a cell population found in peripheral blood. 

Our proprietary technology is based on more than 10 years of clinical data demonstrating the ability of our autologous cell product to regenerate diseased and damaged tissue, which has the potential to generate therapies for a broad range of ischemic diseases such as critical limb ischemia, peripheral artery disease, congestive heart failure and other vascular diseases. 

Hemostemix develops its cell therapy products from a patient’s own blood which is a relatively low risk, cost effective and non-invasive source of therapeutic cells.  The Company has over 91 patents and patent applications in more than 25 jurisdictions.

The Company’s patent portfolio covers five patent families which include:

  • Regulating stem cells
  • Regulating stem cells
  • In vitro techniques for use with stem cells
  • Production from blood of cells of neural lineage
  • Automated cell therapy